Benfotiamine attenuates inflammatory response in LPS stimulated BV-2 microglia

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Bozic, Iva ^a   Savic, Danijela ^a   Laketa, Danijela ^a   Bjelobaba, Ivana ^a   Milenkovic, Ivan ^b   Pekovic, Sanja ^a   Nedeljkovic, Nadezda ^a   Lavrnja, Irena ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENFOTIAMINE; CYCLOOXYGENASE 2; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 2; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BENPHOTHIAMINE; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; THIAMINE;

ACTIN FILAMENT; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE EXPRESSION; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CELL SURVIVAL; CYTOLOGY; CYTOSKELETON; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; WESTERN BLOTTING;

MURINAE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE 2; CYTOKINES; CYTOSKELETON; HSP70 HEAT-SHOCK PROTEINS; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THIAMINE;

EID: 84923197617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118372     Document Type: Article

References (73)

1. Gertig U, Hanisch UK (2014) Microglial diversity by responses and responders. Front Cell Neurosci 8:101. doi: 10.3389/fncel.2014.00101 PMID: 24744702
2. Prinz M, Mildner A (2011) Microglia in the CNS: immigrants from another world. Glia. 59:177-87. doi: 10.1002/glia.21104 PMID: 21125659
3. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19:312-8. PMID: 8843599
4. Luo XG, Chen SD (2012) The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener. 24; 1:9. doi: 10.1186/2047-9158-1-9
5. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 8:57-69. PMID: 17180163
6. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev. 91:461-553. doi: 10.1152/physrev.00011.2010 PMID: 21527731
7. Savic D, Stojiljkovic M, Lavrnja I, Parabucki A, Bjelobaba I, Nedeljkovic N, et al. (2014) Ribavirin shows immunomodulatory effects on activated microglia, Immunopharmacol Immunotoxicol 36:433-441. doi: 10.3109/08923973.2014.971962 PMID: 25393884
8. Graeber MB, Streit WJ (2010) Microglia: biology and pathology. Acta Neuropathol 119:89-105. doi: 10.1007/s00401-009-0622-0 PMID: 20012873
9. Bordt EA, Polster BM (2014) NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: a bipartisan affair? Free Radic Biol Med 76C:34-46. doi: 10.1016/j.freeradbiomed.2014.07.033
10. Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol. 6:193-201. doi: 10.1038/nrneurol.2010.17 PMID: 20234358
11. McCarty MF (2006) Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med Hypotheses. 67:251-69. PMID: 16513287
12. Enomoto KI, Edwards C (1985) Thiamine blockade of neuromuscular transmission. Brain Research 358: 316-323. doi: 10.1016/0006-8993(85)90976-x PMID: 2416387
13. Ba A (2008) Metabolic and Structural Role of Thiamine in Nervous Tissues. Cellular and Molecular Neurobiology 28: 923-931. doi: 10.1007/s10571-008-9297-7 PMID: 18642074
14. Pácal L, Kuricová K, Kaòková K (2014) Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation? World J Diabetes 15; 5: 288-295.
15. Ke ZJ, DeGiorgio LA, Volpe BT, Gibson GE (2003) Reversal of thiamine deficiency-induced neurodegeneration. J Neuropathol Exp Neurol 62:195-207. PMID: 12578229
16. Jhala SS, Hazell AS (2011) Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism. Neurochem Int. 58:248-60. doi: 10.1016/j.neuint.2010.11.019 PMID: 21130821
17. Becker JT, Furman MMR, Panisset M, Smith C (1990). Characteristics of the memory loss of a patient with Wernicke-Korsakoff's syndrome without alcoholism. Neuropsychologica, 28:171-179.
18. Wang D, Hazell AS (2010) Microglial activation is a major contributor to neurologic dysfunction in thiamine deficiency. Biochem Biophys Res Commun. 402:123-8. doi: 10.1016/j.bbrc.2010.09.128 PMID: 20932820
19. Ji Z, Fan Z, Zhang Y, Yu R, Yang H, Zhou C et al. (2014) Thiamine deficiency promotes T cell infiltration in experimental autoimmune encephalomyelitis: the involvement of CCL2. J Immunol. 193:2157-67. doi: 10.4049/jimmunol.1302702 PMID: 25063874
20. Fujiwara M, Sasakawa S, Itokawa Y, Ikeda K (1964) Affinity of thiamine propyl disulphide-S35 to organs. J Viaminol (Kyoto), 10:79-87.
21. Bitsch R, Wolf M, Moller J, Heuzeroth L, Grüneklee D (1991) Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab, 35:292-296. PMID: 1776825
22. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294-299. doi: 10.1038/nm834 PMID: 12592403
23. Wu S, Ren J (2006) Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-α . Neurosci Lett 394:158-162. doi: 10.1016/j.neulet.2005.10.022 PMID: 16260089
24. Woelk H, Lehrl S, Bitsch R, Kopcke W (1998) Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol. 33:631-638. PMID: 9872352
25. Volvert ML, Seyen S, Piette M, Evrard B, Gangolf M, Plumier RC, et al. (2008) Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 8:10. doi: 10.1186/1471-2210-8-10 PMID: 18549472
26. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M (2006) Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 281: 9307-9313. doi: 10.1074/jbc.M600418200 PMID: 16452468
27. Fujiwara M (1954) Allithiamine: a newly found derivative of vitamin B. Journal of Biochemistry (Tokyo) 2, 273-285.
28. Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J (2006) High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J ApplPhysiol 1: 150-156. doi: 10.1152/japplphysiol.00988.2005
29. Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A (2010) The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 61: 482-488. doi: 10.1016/j.phrs.2010.02.008 PMID: 20188835
30. Manzardo AM, He J, Poje A, Penick EC, Campbell J, Butler MG (2013) Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence. Drug Alcohol Depend. 133:562-70. doi: 10.1016/j.drugalcdep.2013.07.035 PMID: 23992649
31. Pan X, Gong N, Zhao J, Yu Z, Gu F, Chen J, et al. (2010) Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 133:1342-51. doi: 10.1093/brain/awq069 PMID: 20385653
32. Sun XJ, Zhao L, Zhao N, Pan XL, Fei GQ, Jin LR, et al. (2012) Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose. Neurosci Bull. 28:561-6. doi: 10.1007/s12264-012-1264-0 PMID: 22961478
33. Yadav UC, Subramanyam S, Ramana KV (2009) Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci 50:2276-82. doi: 10.1167/iovs.08-2816 PMID: 19136698
34. Yadav UC, Kalariya NM, Srivastava SK, Ramana KV (2010) Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med 48:1423-34. doi: 10.1016/j.freeradbiomed.2010.02.031 PMID: 20219672
35. Shoeb M, Ramana KV (2012) Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med 52:182-190. doi: 10.1016/j.freeradbiomed.2011.10.444 PMID: 22067901
36. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F (1990) Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 27: 229-37. PMID: 2110186
37. Bajić A, Spasić M, Andjus PR, Savić D, Parabucki A, Nikolić-Kokić A, et al. (2013) Fluctuating vs. continuous exposure to H2O2: the effects on mitochondrial membrane potential, intracellular calcium, and NF-κB in astroglia. PLoS One 8:e76383. doi: 10.1371/journal.pone.0076383 PMID: 24124554
38. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-94. doi: 10.1038/nn1997 PMID: 17965659
39. Eggen BJ, Raj D, Hanisch UK, Boddeke HW (2013) Microglial phenotype and adaptation. J NeuroimmunePharmacol 8:807-23. doi: 10.1007/s11481-013-9490-4 PMID: 23881706
40. Hanisch UK (2013) Functional diversity of microglia - how heterogeneous are they to begin with? Front Cell Neurosci 7:65. doi: 10.3389/fncel.2013.00065 PMID: 23717262
41. Abd-El-Basset EM (2000) Bacterial Endotoxin Induces Changes in the Organization and Expression of Actin and Modulation of the Cell Membrane of Microglia. Med Principles Pract 9:81-90.
42. Abd-El-Basset EM, Prashanth J, Ananth Lakshmi KVV (2004) Up-Regulation of Cytoskeletal Proteins in Activated Microglia. Med Princ Pract 13:325-333. doi: 10.1159/000080469 PMID: 15467307
43. Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K, et al. (2001) Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci. 21:1975-82. PMID: 11245682
44. Murphy S (2000) Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 29:1-13. PMID: 10594918
45. Pautz A, Art J, Hahn S, Nowag S, Voss C, Kleinert H (2010) Regulation of the expression of inducible nitric oxide synthase. Nitric Oxide 23:75-93. doi: 10.1016/j.niox.2010.04.007 PMID: 20438856
46. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-10. PMID: 15453089
47. Patterson H, Nibbs R, McInnes I, Siebert S (2014) Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol. 176:1-10. doi: 10.1111/cei.12248 PMID: 24313320
48. Hehlgans T, Pfeffer K (2005) The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 115: 1-20. doi: 10.1111/j.1365-2567.2005.02143.x PMID: 15819693
49. Park KM, Bowers WJ (2010) Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22: 977-983. doi: 10.1016/j.cellsig.2010.01.010 PMID: 20096353
50. Shafer LL, McNulty JA, Young MR (2002) Brain activation of monocyte-lineage cells: involvement of interleukin-6. Neuroimmunomodulation 10:295-304. doi: 10.1159/000069973 PMID: 12759566
51. Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T (1999) Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem 72: 1466-71. doi: 10.1046/j.1471-4159.1999.721466.x PMID: 10098850
52. Seo DR, Kim KY, Lee YB (2004) Interleukin-10 expression in lipopolysaccharide-activated microglia is mediated by extracellular ATP in an autocrine fashion. Neuroreport. 15:1157-61. PMID: 15129165
53. Huang WC, Lin YS, Wang CY, Tsai CC, Tseng HC, Chen CL, et al. (2009) Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128:e275-e286. doi: 10.1111/j.1365-2567.2008.02959.x PMID: 19175796
54. Günzl P, Bauer K, Hainzl E, Matt U, Dillinger B, Mahr B, et al. (2010) Anti-inflammatory properties of the PI3K pathway are mediated by IL-10/DUSP regulation. J Leukoc Biol 88:1259-69. doi: 10.1189/jlb.0110001 PMID: 20884649
55. Kaminska B, Gozdz A, Zawadzka M, Ellert-Miklaszewska A, Lipko M (2009) MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target.Anat Rec (Hoboken) 292:1902-13. doi: 10.1002/ar.21047 PMID: 19943344
56. Giri S, Rattan R, Singh AK, Singh I (2004) The 15-deoxy-delta12, 14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol 173:5196-5208. doi: 10.4049/jimmunol.173.8.5196 PMID: 15470065
57. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62. PMID: 17183360
58. Smith JA, Das A, Ray SK, Banik NL (2012) Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 87: 10-20. doi: 10.1016/j.brainresbull.2011.10.004 PMID: 22024597
59. Fiebich BL, Lieb K, Engels S, Heinrich M (2002) Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol 132:18-24. PMID: 12417429
60. Watters J, Sommer J, Pfeiffer Z, Prabhu U, Guerra A, Bertics P (2002) A differential role for the mitogen-activated proteinkinases in lipopolysaccharide signaling. J Biol Chem 277: 9077-9087. PMID: 11786532
61. Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA (2008) Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem. 107: 557-69. doi: 10.1111/j.1471-4159.2008.05633.x PMID: 18717813
62. Kim YH, Koh HK, Kim DS (2010) Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. Int Immunopharmacol 10: 1560-72. doi: 10.1016/j.intimp.2010.09.007 PMID: 20932499
63. Waetzig V, Czeloth K, Hidding U, Mielke K, Kanzow M, Brecht S, et al. (2005) c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia. 50: 235-46. PMID: 15739188
64. Nakamichi K, Saiki M, Kitani H, Kuboyama Y, Morimoto K, Takayama-Ito M, et al. (2007) Roles of NF-kappaB and MAPK signaling pathways in morphological and cytoskeletal responses of microglia to double-stranded RNA. Neurosci. Lett 414: 222-7. PMID: 17284350
65. Ohsawa K, Sanagi T, Nakamura Y, Suzuki E, Inoue K, Kohsaka S (2012) Adenosine A3 receptor is involved in ADP-induced microglial process extension and migration. J Neurochem. 121: 217-27. doi: 10.1111/j.1471-4159.2012.07693.x PMID: 22335470
66. Waetzig V, Herdegen T (2004) Neurodegenerative and physiological actions of c-Jun N-terminal kinases in the mammalian brain. Neurosci. Lett 361:64-7. doi: 10.1016/j.neulet.2004.02.041 PMID: 15135894
67. Svensson C, Fernaeus SZ, Part K, Reis K, Land T (2010) LPS-induced iNOS expression in Bv-2 cells is suppressed by an oxidative mechanism acting on the JNK pathway - a potential role for neuroprotection. Brain Res 1322:1-7. doi: 10.1016/j.brainres.2010.01.082 PMID: 20138851
68. Zhao H, Cheng L, Liu Y, Zhang W, Maharjan S, Cui Z, et al. (2014) Mechanisms of anti-inflammatory property of conserved dopamine neurotrophic factor: inhibition of JNKsignaling in lipopolysaccharide-induced microglia. J Mol Neurosci 52: 186-92. PMID: 24078520
69. Saponaro C, Cianciulli A, Calvello R, Dragone T, Iacobazzi F, Panaro AM (2012) The PI3K/Akt pathway is required for LPS activation of microglial cells. Immunopharmacol Immunotoxicol 34: 858-65. doi: 10.3109/08923973.2012.665461 PMID: 22397361
70. Kacimi R, Giffard RG, Yenari MA (2011) Endotoxin-activated microglia injure brain derived endothelial cells via NF-κB, JAK-STAT and JNK stress kinase pathways. J Inflamm (Lond) 8:7. doi: 10.1186/1476-9255-8-7
71. Nam KN, Son MS, Park JH, Lee EH (2008) Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications. Neuropharmacology 55:819-25. doi: 10.1016/j.neuropharm.2008.06.065 PMID: 18657551
72. Wen J, Ribeiro R, Zhang Y (2011) Specific PKC isoforms regulate LPS-stimulated iNOS induction in murine microglial cells. J Neuroinflammation. 8:38. doi: 10.1186/1742-2094-8-38 PMID: 21510893
73. Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, et al. (2006) Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. Neurosci Lett. 396:1-6. doi: 10.1016/j.neulet.2005.11.004 PMID: 16324785